Loading company…
Shanghai Junshi Biosciences develops monoclonal antibody drugs, including an anti-PD-1 antibody, from its base in Shanghai.
Based in Shanghai, China and established in 2012, Shanghai Junshi Biosciences Co., Ltd. discovers and develops monoclonal antibody drugs. It has R&D centers in Shanghai, Suzhou, San Francisco and Maryland, and production sites in Suzhou and Shanghai. CEO Dr. Ning Li previously worked at the U.S. Food and Drug Administration. The company received IND approval for its anti-PD-1 monoclonal antibody in December 2015 and has developed 28 innovative drugs and 2 bioanalogues.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in